Moesin Is a Novel Biomarker of Endothelial Injury in Sepsis
Yikun Chen(Soochow University), Jianan Huang(Soochow University)
Cited by 15
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|Annals of Oncology|2013|120
Role of IL-17 in LPS-induced acute lung injury: an<i>in vivo</i>study
|Oncotarget|2017|60